Sulak Anandabaskaran
YOU?
Author Swipe
View article: Diagnosing Crohn’s disease in presumed cryptoglandular perianal fistulas: an expert Delphi consensus on early identification of patients at risk of Crohn’s disease in perianal fistulas (PREFAB)
Diagnosing Crohn’s disease in presumed cryptoglandular perianal fistulas: an expert Delphi consensus on early identification of patients at risk of Crohn’s disease in perianal fistulas (PREFAB) Open
Background The aim of this Delphi study was to reach consensus on a new clinical decision tool to help identify or exclude Crohn’s disease (CD) in patients with perianal fistula(s) (PAF). Methods A panel of international experts in the fie…
View article: Perianal Fistulizing Crohn’s Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care
Perianal Fistulizing Crohn’s Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care Open
This article provides an overview of the system's use in clinical practice. It aims to enable clinicians to have a pragmatic and patient goal-centered approach to medical and surgical management options for individual patients with PFCD.
View article: P991 Serum anti-TNF levels correlate with tissue levels in perianal fistulising Crohn’s Disease
P991 Serum anti-TNF levels correlate with tissue levels in perianal fistulising Crohn’s Disease Open
Background Perianal fistulising Crohn’s Disease (PFCD) affects up to 25% of patients and remains difficult to treat despite medical and surgical advancements.1 Perianal fistulas have unique immunopathogenic features associated with an aggr…
View article: P934 A delphi consensus on the optimisation of medical and surgical therapy in perianal fistulising Crohn’s disease, targeted at individual TOpCLASS classification groups
P934 A delphi consensus on the optimisation of medical and surgical therapy in perianal fistulising Crohn’s disease, targeted at individual TOpCLASS classification groups Open
Background Perianal fistulising Crohn’s Disease (PFCD) is a challenging phenotype of IBD associated with poor outcomes. Classically, fistulae have been classified anatomically and guidelines have been generalised, with a lack of appreciati…
View article: Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib Open
Background and Aims We sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with inflammatory bowel disease [IBD]. Methods W…
View article: Where Are We and Where to Next?—The Future of Perianal Crohn’s Disease Management
Where Are We and Where to Next?—The Future of Perianal Crohn’s Disease Management Open
Perianal fistulizing Crohn’s Disease (pCD) affects about 25% of patients with Crohn’s Disease (CD). It remains a difficult entity to manage with a therapeutic ceiling of treatment success despite improving medical and surgical management. …
View article: Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study Open
View article: Invariant natural killer T-cell and CD4<sup>+</sup>T-cell derived IL22 is a regulator of epithelial-to-mesenchymal transition and extracellular matrix remodelling in perianal fistulas
Invariant natural killer T-cell and CD4<sup>+</sup>T-cell derived IL22 is a regulator of epithelial-to-mesenchymal transition and extracellular matrix remodelling in perianal fistulas Open
Background and aims Perianal fistulization is a challenging phenotype of Crohn’s disease (CD). Unravelling the cytokine networks and cellular mediators driving tissue injury in perianal CD (pCD) will help inform much needed novel treatment…
View article: P535 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy
P535 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy Open
Background Patients with Inflammatory bowel disease (IBD) receiving anti-TNF or JAK-inhibitor therapy have attenuated responses to COVID-19 vaccination. We aimed to determine how IBD treatments affect neutralising antibody responses agains…
View article: Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine Open
\n Contains fulltext :\n 291656.pdf (Publisher’s version ) (Open Access)\n
View article: COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study Open
BACKGROUND: COVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We sought to assess whether immunosuppressive treatments were ass…
View article: Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB Open
View article: COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study Open
BACKGROUND: The effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to determine whether COVID-19 vaccine-induced antibody responses w…
View article: OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab
OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab Open
Background Robust COVID-19 vaccine-induced antibody (Ab) responses are important for protective anti-viral immunity. Data are urgently needed to determine whether vaccine-induced immunity is impacted by commonly used immunosuppressive drug…
View article: COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or Vedolizumab
COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or Vedolizumab Open
View article: A predictive model for non-completion of an intensive specialist obesity service in a public hospital: a case-control study
A predictive model for non-completion of an intensive specialist obesity service in a public hospital: a case-control study Open
View article: Su1659 – Positive Faecal Occult Blood Test After a Previous Negative Colonoscopy - to Scope Or Not?
Su1659 – Positive Faecal Occult Blood Test After a Previous Negative Colonoscopy - to Scope Or Not? Open